Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
0.5869
+0.0169 (2.96%)
Adaptimmune is a biotechnology company focused on developing T-cell therapy to treat cancer
The company specializes in harnessing the power of the immune system, particularly using engineered T-cell receptors (TCRs), to target and eliminate cancer cells more effectively. Adaptimmune’s innovative approach aims to improve patient outcomes in various cancers by personalizing therapies to the individual’s unique tumor characteristics. Through ongoing research and clinical trials, the company strives to bring transformative treatment options to patients suffering from life-threatening malignancies.
ADAP stock results show that Adaptimmune Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large joints. Tecelra, the first engineered cell therapy for solid tumors in the U.S., showed a 43% ORR and a median response duration of six months.
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Shares of Marvell Technology, Inc. (NASDAQMRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
ADAP stock results show that Adaptimmune Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
